However, several problems remain in the treatment of pancreatic cancer: more than half of patients do not respond to PDL1/PD-1 inhibitor blockade therapy, and there are no current biological markers to distinguish responders from nonresponders [29]. Here, CD274 is linked to pancreatic neoplasm.